

**Supplementary S1:** Outcome measures at the end of 12 months according to injection subtype

	<b>nAMD (N=19)</b>	<b>DMO (N=20)</b>	<b>RVO (N=17)</b>	<b>P*</b>
<b>Bevacizumab</b>				
BCVA change (ETDRS letters)	6 (-9 to 25)	1 (0 to 16)	15 (-20 to 35)	<b>0.020<sup>†</sup></b>
CMT change (µm)	-40 (-303 to -1)	-67 (-482 to 50)	-134 (-475 to 43)	0.202 <sup>‡</sup>
Number of Injections	10 (6 to 17)	8 (3 to 13)	10 (5 to 13)	0.206
Final BCVA (ETDRS letters)	68 (20 to 80)	71 (11 to 85)	67 (0 to 78)	0.333
Final CMT(µm)	259 (215 to 524)	293 (226 to 460)	293 (222 to 710)	0.057
<b>Mixed injection</b>	<b>N=22</b>	<b>N=13</b>	<b>N=9</b>	
BCVA change (ETDRS letters)	2.5 (-30 to 40)	2 (-5 to 20)	10 (-18 to 22)	0.573 <sup>‡</sup>
CMT change (µm)	-90 (-340 to 81)	-54 (-455 to 10)	-172 (-478 to -14)	<b>0.040<sup>§</sup></b>
Number of Injections	11 (5 to 14)	10 (7 to 12)	10 (9 to 13)	0.239

Abbreviations: BCVA=best corrected visual acuity; CMT=central macular thickness; DMO=diabetic macular oedema; ETDRS=early treatment diabetic retinopathy study; nAMD=neovascular age-related macular degeneration; RVO=retinal vein occlusion

Data are medians (range). \*p-values are global p-values testing for a difference between any of the diseases. (Kruskal-Wallis for continuous variables). For comparisons that are significant at the global level, adjusted pairwise p-values for individual study comparisons are reported. Significant p-values are bolded.

<sup>†</sup> nAMD vs DMO p=0.471; **DMO vs RVO p=0.015**; nAMD vs RVO p=0.480

<sup>§</sup> nAMD vs DMO p=1.000; **DMO vs RVO p=0.050**; nAMD vs RVO p=0.085

**Note:** <sup>‡</sup> our sub-cohort might be under-powered to detect any statistical significance due to very small sample size